Table IV.

Study of links between blood calprotectin level in patients with juvenile idiopathic arthritis (JIA) prior to discontinuation of treatment and flare risk

Follow-up, flares/in total (% of flares)	Calprotectin in patients with JIA at visit 0, ng/ml, median (min–max)		p (Mann-Whitney criteria)
	Flares	No flares
At 3 months n = 5/54 (9.3%)	1,700 (920–24,000)	1,500 (200–30,000)	0.35
At 6 months n = 3/48* (6.3%)	1,300 (600–1,900)	1,500 (200–30,000)	0.70
In 12 months n = 13/45 (28.9%)	1,100 (200–30,000)	1,650 (200–11,200)	0.16

^*One patient withdrew from the study at 3 months.